27.08.2018
Evotec AG DE0005664809
DGAP-News: EVOTEC AND CENTOGENE SIGN GLOBAL STRATEGIC PARTNERSHIP ON DRUG DISCOVERY PROJECTS IN RARE GENETIC DISEASES
DGAP-News: Evotec AG / Key word(s): Miscellaneous
EVOTEC AND CENTOGENE SIGN GLOBAL STRATEGIC PARTNERSHIP ON DRUG DISCOVERY
PROJECTS IN RARE GENETIC DISEASES
27.08.2018 / 07:29
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
EVOTEC AND CENTOGENE SIGN GLOBAL STRATEGIC PARTNERSHIP ON DRUG DISCOVERY
PROJECTS IN RARE GENETIC DISEASES
- JOINT DRUG DISCOVERY PROJECTS COMBINE CENTOGENE'S PATIENT ACCESS AND
BIOMARKER EXPERTISE WITH EVOTEC'S LEADING IPSC PLATFORM
Hamburg, Rostock, Germany, 27 August 2018:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today
announced that CENTOGENE AG, the worldwide leader in elucidating rare
disease genetics for patients, clinicians and pharmaceutical partners, and
Evotec entered into a global strategic collaboration agreement for joint
drug discovery projects, developing compounds to treat rare genetic
diseases.
Evotec and CENTOGENE initiated the collaboration to develop a strategic
high-throughput platform for testing novel small molecules in rare
hereditary metabolic diseases.
The collaboration brings together Evotec's leading induced pluripotent stem
cell ("iPSC") platform and broad drug discovery capabilities with
CENTOGENE's unique medical and genetic insights. In particular, detailed
genotype-phenotype data enables rapid biomarker development using patient
primary cells.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "The
collaboration between Evotec and CENTOGENE is focused on developing
iPSC-based patient-derived disease models and suitable biomarkers for rare
genetic diseases. A perfect match between highly complementary platforms and
companies with the potential to open a new chapter in the translatability of
pre-clinical discovery efforts into clinic benefits."
"The identification and development of innovative small molecules to treat
rare, hereditary conditions is particularly challenging because of the
absence of adequate cellular models and the general lack of specific
biomarkers to monitor the different diseases. With this innovative
collaboration between Evotec and CENTOGENE, we can accelerate the
development of new drugs. CENTOGENE is fully committed to explore any given
opportunity to discover new ways of helping patients and their families,
together with its partners", said Dr Arndt Rolfs, CEO of CENTOGENE.
No financial details were disclosed.
ABOUT CENTOGENE
CENTOGENE unlocks the power of genetic insights to improve the quality of
life of patients with genetic rare diseases. We achieve this through
knowledge created by our worldwide diagnostic testing services incorporating
global diversity, the world's leading proprietary human genetic
interpretation database, CentoMD(R) and solutions for pharmaceutical
companies developing life-changing orphan drugs. As one of the most
diversified and largest genetic testing companies worldwide, CENTOGENE is
dedicated to transforming the science of genetic information into solutions
and hope for patients and their families. www.centogene.com; www.centoMD.com.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide and our more than 2,400
employees provide the highest quality stand-alone and integrated drug
discovery and development solutions. We cover all activities from
target-to-clinic to meet the industry's need for innovation and efficiency
in drug discovery and development (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuronal diseases, diabetes and
complications of diabetes, pain and inflammation, oncology, infectious
diseases, respiratory diseases and fibrosis. On this basis, Evotec has built
a broad and deep pipeline of approx. 100 co-owned product opportunities at
clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has
established multiple long-term alliances with partners including Bayer,
Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi,
Takeda, UCB and others. For additional information please go to
www.evotec.com and follow us on Twitter @EvotecAG.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking statements
are neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
27.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard);
Regulated Unofficial Market in Dusseldorf, Hamburg,
Hanover, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
717575 27.08.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT